Relationship between occupational risk factors and severity markers of systemic sclerosis

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1713-1718

  Magnant, Julie ^a   De Monte, Michèle ^b   Guilmot, Jean Louis ^c   Lasfargues, Gérard ^d   Diot, Patrice ^b   Asquier, Elisabeth ^e   Degenne, Danielle ^f   Boissinot, Eric ^b   Diot, Elisabeth ^g,h  

^a INSERM   (France)

^b Groupe de Pneumologie   (France)

^c Service de Médecine Interne B

^d Institut de Médecine du Travail du Val de Loire   (France)

^e Groupement d'Imagerie Médicale ^*  (France)

^f Laboratoire d'Immunologie

^g Service de Médecine Interne B   (France)

^h CHU BRETONNEAU   (France)

Author keywords

Occupational disease; Scleroderma; Severity factors

Indexed keywords

CENTROMERE ANTIBODY; DNA TOPOISOMERASE INHIBITOR; EPOXY RESIN; SILICON DIOXIDE; SOLVENT;

ADULT; AGED; ARTICLE; DIFFUSE SCLERODERMA; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LIMITED SCLERODERMA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; WELDING FUME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCCUPATIONAL EXPOSURE; PROBABILITY; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 24944457135     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Masi AT, Rodnan GP, Medsger TA, et al. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
2. Medsger TA, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
3. Diot E, Lesire V, Guilmot JL, et al. Systemic sclerosis and occupational risk-factors: a case-control study. Occup Environ Med 2002;59:545-9.
4. Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med 1995;28:603-8.
5. Haustein U, Ziegler V, Herrman K. Environmental scleroderma. Clin Dermatol 1994;12:467-73.
6. Goldman J. Connective tissue disease in people exposed to organic chemical solvents: systemic sclerosis (scleroderma) in dry cleaning plant and aircraft industry workers. J Clin Rheumatol 1996;2:185-90.
7. Nietert PJ, Sutherland SE, Silver RM, et al. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum 1998;41:1111-8.
8. Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Dosemeci M. Solvent oriented hobbies and the risk of systemic sclerosis. J Rheumatol 1999;26:2369-72.
9. Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
10. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6:5-40.
12. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of measurement of transfer factor (diffusing capacity). Eur Respir J 1993;6:41-52.
13. Keogh BA, Cristal RG. Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial lung disease. What does it tell us? Chest 1980;78:856-65.
14. Wells AU, Hansell DM, Rubens MB, Cullinana P, Black CM, du Bois RM. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993;148:1076-82.
15. Diot E, Diot P, Valat C, et al. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with systemic sclerosis. Eur Respir J 1995;8:1559-65.
16. Warrick JH, Bhalla M, Shabel S, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18:1520-8.
17. Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on high resolution CT and pulmonary function in systemic sclerosis. Chest 1998;114:1623-9.
18. Diot E, Giraudeau B, Diot P, et al. Is antitopoisomerase 1 a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999;116:715-20.
19. Nyambi PN, Nkengasong J, Lewi PJ, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:6235-43.
20. de Monte M, Nonnenmacher H, Brignon N, Ullmann M, Martin JP. A multivariate statistical analysis to follow the course of disease after infection of cats with different strains of the feline immunodeficiency virus (FIV). J Virol Methods 2002;103:157-70.
21. Lebart L, Morineau A, Warwick KM. Multivariate descriptive statistical analysis. New York: John Wiley and Sons; 1984.
22. Altman RD, Medsger TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
23. MacHugh NJ, Whyte J, Harvey G, Haustein UF. Antitopoisomerase 1 antibodies in silica-associated systemic sclerosis. Arthritis Rheum 1994;37:1198-205.
24. Rustin MHA, Bull HA, Ziegler V, et al. Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 1990;123:725-34.
25. Haustein UH, Anderegg U, Rustin MHA. Silica induced scleroderma - clinical and experimental aspects. J Rheumatol 1998;25:1917-26.
26. Czirjak L, Kumánovics G. Exposure to solvents in female patients with scleroderma. Clin Rheumatol 2002;21:114-8.
27. Garabrant DH, Dumas C. Epidemiology of organic solvents and connective tissue disease. Arthritis Res 2000;2:5-15.
28. Sluis-Cremer GK, Hessel PA, Nizdo EH, Churchill AR, Zeiss EA. Silica, silicosis, and progressive systemic sclerosis. Br J Ind Med 1985;4:838-43.
29. Aryal BK, Khuder SA, Schaub EA. Meta-analysis of systemic sclerosis and exposure to solvents. Am J Ind Med 2001;40:271-4.
30. Garabrant DH, Lacey JV Jr, Laing TJ, et al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157:493-500.
31. de Shazo RD. Current concepts about the pathogenesis of silicosis and asbestosis. J Allergy Clin Immunol 1982;70:41-9.
32. Bovenzi M, Barbone F, Bettava, Tommasini M, Versini W. Scleroderma and occupational exposure. Scand J Work Environ Health 1995;21:289-92.
33. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 2003;278:13008-15.